Francoise Blanchot-Picarel

Prevalence of Autism Spectrum Disorder and Co-Morbidities in Children and Adolescents: A Systematic Literature Review.

Journal: Focus (American Psychiatric Publishing)

Published: April 29, 2024

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study.

Journal: European child & adolescent psychiatry

Published: June 16, 2023

Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review.

Journal: Frontiers in psychiatry

Published: July 20, 2021

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Journal: Advances in therapy

Published: September 14, 2020

Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.

Journal: Clinical drug investigation

Published: July 31, 2020

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

Journal: Human psychopharmacology

Published: February 11, 2020

Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.

Journal: Trials

Published: November 07, 2018

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Journal: Journal of affective disorders

Published: February 16, 2018

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: November 27, 2017

Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.

Journal: Human psychopharmacology

Published: June 28, 2017

Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.

Journal: International clinical psychopharmacology

Published: April 07, 2017

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: September 21, 2016

Prevalence of Autism Spectrum Disorder and Co-Morbidities in Children and Adolescents: A Systematic Literature Review.

Prevalence of Autism Spectrum Disorder and Co-Morbidities in Children and Adolescents: A Systematic Literature Review.

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study.

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study.

Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review.

Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review.

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.

Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.

Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.

Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.

Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.

Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.